Capricor Therapeutics (CAPR) Short term Debt (2010 - 2023)

Capricor Therapeutics' Short term Debt history runs 8 years deep, the most recent figure standing at $18628.0 for Q2 2023.

• In Q2 2023, Short term Debt fell 80.21% year-over-year to $18628.0; the TTM figure through Jun 2023 stood at $18628.0 (down 80.21% YoY), while the FY2022 annual figure was $89234.0, down 85.11% from the prior year.
• Short term Debt was $18628.0 for Q2 2023 at Capricor Therapeutics, roughly flat from $18716.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $599388.0 in Q4 2021 to a low of $18628.0 in Q2 2023.
• Historically, Short term Debt has averaged $211300.7 across 3 years, with a median of $89234.0 in 2022.
• Biggest YoY gain for Short term Debt was 80.21% in 2023; the steepest drop was 96.74% in 2023.
• A 3-year view of Short term Debt shows it stood at $599388.0 in 2021, then sank by 85.11% to $89234.0 in 2022, then slumped by 79.12% to $18628.0 in 2023.
• The last three Short term Debt figures came in at $18628.0 (Q2 2023), $18716.0 (Q1 2023), and $89234.0 (Q4 2022), per Business Quant data.